A Phase 3 trial of Liquidia Technologies’ LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH) is underway, the company said. The study is expected to enroll a minimum of 100 PAH patients in the US, with topline data anticipated in 2019.
LIQ861, a dry powder formulation based on Liquidia’s PRINT particle engineering technology, is one of two products in the company’s pipeline. At least one other dry powder formulation for inhalation developed by Liquidia and licensed to GSK is in development.
Liquidia Technologies CEO Neal Fowler said, “We are committed to improving the daily experience of those living with PAH by advancing the clinical development of LIQ861. LIQ861 shows the potential of our PRINT® technology to optimize safety, efficacy and convenience of therapeutics. The initiation of our trial marks an important milestone for Liquidia, for those living with PAH and for the PAH community at large. We believe that we are well positioned to advance LIQ861 through Phase 3 clinical development.”
Read the Liquidia Technologies press release.
